.png){kind=logo}
Sample card — sent with every shipment
- Member
- E. Whitfield · ID 10284
- Prescriber
- Dr. Margaret Whitfield, MD
- Pharmacy
- [Named at prescription] · State license disclosed with your Rx
- Active ingredient
- Semaglutide
- Concentration
- 2.5 mg / mL
- Vehicle
- Sterile water for injection, USP
- Beyond-use date
- 2026-05-14
- Lot
- WS-2604-0091
- FDA status
- Compounded, not FDA-approved
This card accompanies every shipment. Questions about compounding, concentration, or alternatives: 24/7 clinical support line.
A printed card accompanies every shipment. It lists the active ingredient, the concentration, the vehicle, the beyond-use date, the lot number, the pharmacy name and state license, the prescriber, and the FDA status of the medication. No field is omitted. Members who cannot read their card for any reason can call the 24/7 clinical line.
Compounding is the preparation of a medication by a state-licensed pharmacy for a specific patient. It is lawful. It is regulated. It is not FDA-approved in the sense that brand-name medications are reviewed and approved as finished products.
Compounding exists because some patients need a concentration, a combination, or a dosage form that a commercial manufacturer does not produce. During a drug shortage, compounding also allows access to the same active ingredient a branded product contains. Compounding is not a copy-paste operation. It is performed by trained pharmacists under state boards of pharmacy.
Weightstry's policy is that members should not have to interpret any of this. Your provider discusses the specific medication prescribed, its active ingredient, potential risks and side effects, and any FDA-approved alternatives before a prescription is written.
We work with a small number of state-licensed compounding pharmacies. Each partner is named on the Transparency Card that ships with every order, so the dispensing pharmacy is never anonymous at the point of receipt.
Weightstry is LegitScript-certified for healthcare merchant practice. The certification confirms compliance with applicable state and federal healthcare regulations and is renewed under LegitScript's ongoing monitoring.
In March 2026, the U.S. Food and Drug Administration issued warning letters to 30 telehealth companies for alleged illegal marketing of compounded GLP-1 medications. Weightstry is not on that list. The full letter roster is available through the FDA press announcement.
Reference: FDA warns 30 telehealth companies against illegal marketing
When information is favorable, we publish it. When information is unfavorable, we publish it. When we do not know, we say so. The aim is a practice that withstands its own paperwork.